Cited by

• The current debate concerning beta-agonists in asthma: a review.

  Chung KF. Chung KF. J R Soc Med. 1993 Feb;86(2):96-100. J R Soc Med. 1993. PMID: 8094459 Free PMC article. Review. No abstract available.
• Regular treatment with salmeterol for chronic asthma: serious adverse events.

  Cates CJ, Cates MJ. Cates CJ, et al. Cochrane Database Syst Rev. 2008 Jul 16;2008(3):CD006363. doi: 10.1002/14651858.CD006363.pub2. Cochrane Database Syst Rev. 2008. PMID: 18646149 Free PMC article.
• Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.

  Walters EH, Gibson PG, Lasserson TJ, Walters JA. Walters EH, et al. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001385. doi: 10.1002/14651858.CD001385.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253458 Free PMC article.
• Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

  Brogden RN, Faulds D. Brogden RN, et al. Drugs. 1991 Nov;42(5):895-912. doi: 10.2165/00003495-199142050-00010. Drugs. 1991. PMID: 1723379 Review.
• Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

  Walters EH, Walters JA, Gibson PW. Walters EH, et al. Cochrane Database Syst Rev. 2002;2002(4):CD003901. doi: 10.1002/14651858.CD003901. Cochrane Database Syst Rev. 2002. PMID: 12519616 Free PMC article.